Semin Neurol 2018; 38(02): 212-225
DOI: 10.1055/s-0038-1649502
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Multiple Sclerosis

Bassem I. Yamout
1   Department of Neurology-Nehmeh and Therese Tohmeh Multiple Sclerosis Center, American University of Beirut, Beirut, Lebanon
,
Raed Alroughani
2   Division of Neurology, Department of Medicine, Al-Amiri Hospital, Kuwait City, Kuwait
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
23. Mai 2018 (online)

Abstract

Multiple sclerosis (MS) is a chronic central nervous system inflammatory disease of autoimmune etiology, mediated by activated T cells with evolving evidence of a significant contribution from B cells and cells of the innate immune system. The disease is thought to be due to a complex interaction between different genetic and environmental factors. The prevalence of MS is rising all over the world, due on one hand to earlier diagnosis and prolonged survival, and on the other to a true increase in incidence of the disease. The diagnosis of MS remains clinical despite recent advances in diagnostics and relies on demonstrating dissemination in space and time while excluding alternative diagnoses. The Mc Donald diagnostic criteria, with their recent 2017 revision, are currently widely accepted in the MS community. Although no cure is yet available, many disease-modifying therapies (DMTs) have shown different levels of efficacy in preventing relapses, accumulation of lesions on magnetic resonance imaging (MRI), and disability progression. Current treatment strategies include gradual escalation based on clinical and radiological criteria that determine treatment response, or initial induction with high efficacy DMTs especially in patients with an early aggressive course.

 
  • References

  • 1 Goodin DS. The epidemiology of multiple sclerosis: insights to disease pathogenesis. Handb Clin Neurol 2014; 122: 231-266
  • 2 Trojano M, Paolicelli D, Tortorella C. , et al. Natural history of multiple sclerosis: have available therapies impacted long-term prognosis?. Neurol Clin 2011; 29 (02) 309-321
  • 3 Selter RC, Hemmer B. Update on immunopathogenesis and immunotherapy in multiple sclerosis. ImmunoTargets Ther 2013; 2: 21-30
  • 4 Gran B, Hemmer B, Vergelli M, McFarland HF, Martin R. Molecular mimicry and multiple sclerosis: degenerate T-cell recognition and the induction of autoimmunity. Ann Neurol 1999; 45 (05) 559-567
  • 5 Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995; 80 (05) 695-705
  • 6 Garg N, Smith TW. An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis. Brain Behav 2015; 5 (09) e00362
  • 7 Hemmer B, Archelos JJ, Hartung HP. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 2002; 3 (04) 291-301
  • 8 O'Connor KC, Bar-Or A, Hafler DA. The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis. J Clin Immunol 2001; 21 (02) 81-92
  • 9 Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338 (05) 278-285
  • 10 Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004; 14 (02) 164-174
  • 11 Magliozzi R, Howell OW, Reeves C. , et al. A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol 2010; 68 (04) 477-493
  • 12 Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47 (06) 707-717
  • 13 Kinzel S, Weber MS. B cell-directed therapeutics in multiple sclerosis: rationale and clinical evidence. CNS Drugs 2016; 30 (12) 1137-1148
  • 14 Federation MSI. Atlas of MS 2013: Mapping Multiple Sclerosis around the world; 2013. Available at: http://www.atlasofms.org . Accessed April 10, 2017
  • 15 Koch-Henriksen N, Sørensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010; 9 (05) 520-532
  • 16 Heydarpour P, Khoshkish S, Abtahi S, Moradi-Lakeh M, Sahraian MA. Multiple sclerosis epidemiology in Middle East and North Africa: a systematic review and meta-analysis. Neuroepidemiology 2015; 44 (04) 232-244
  • 17 Ascherio A, Munger KL. Epidemiology of multiple sclerosis: from risk factors to prevention-an update. Semin Neurol 2016; 36 (02) 103-114
  • 18 Orton SM, Herrera BM, Yee IM. , et al; Canadian Collaborative Study Group. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 2006; 5 (11) 932-936
  • 19 Westerlind H, Ramanujam R, Uvehag D. , et al. Modest familial risks for multiple sclerosis: a registry-based study of the population of Sweden. Brain 2014; 137 (Pt 3): 770-778
  • 20 Sadovnick AD, Armstrong H, Rice GP. , et al. A population-based study of multiple sclerosis in twins: update. Ann Neurol 1993; 33 (03) 281-285
  • 21 Miretti MM, Walsh EC, Ke X. , et al. A high-resolution linkage-disequilibrium map of the human major histocompatibility complex and first generation of tag single-nucleotide polymorphisms. Am J Hum Genet 2005; 76 (04) 634-646
  • 22 Sawcer S, Hellenthal G, Pirinen M. , et al; International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476 (7359): 214-219
  • 23 Belbasis L, Bellou V, Evangelou E, Ioannidis JP, Tzoulaki I. Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. Lancet Neurol 2015; 14 (03) 263-273
  • 24 Yadav SK, Mindur JE, Ito K, Dhib-Jalbut S. Advances in the immunopathogenesis of multiple sclerosis. Curr Opin Neurol 2015; 28 (03) 206-219
  • 25 Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: noninfectious factors. Ann Neurol 2007; 61 (06) 504-513
  • 26 Handel AE, Williamson AJ, Disanto G, Handunnetthi L, Giovannoni G, Ramagopalan SV. An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. PLoS One 2010; 5 (09) e12496
  • 27 Orton SM, Wald L, Confavreux C. , et al. Association of UV radiation with multiple sclerosis prevalence and sex ratio in France. Neurology 2011; 76 (05) 425-431
  • 28 McDowell TY, Amr S, Culpepper WJ. , et al. Sun exposure, vitamin D and age at disease onset in relapsing multiple sclerosis. Neuroepidemiology 2011; 36 (01) 39-45
  • 29 Munger KL, Zhang SM, O'Reilly E. , et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004; 62 (01) 60-65
  • 30 Simpson Jr S, Taylor B, Blizzard L. , et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 2010; 68 (02) 193-203
  • 31 Smolders J, Menheere P, Kessels A, Damoiseaux J, Hupperts R. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 2008; 14 (09) 1220-1224
  • 32 James E, Dobson R, Kuhle J, Baker D, Giovannoni G, Ramagopalan SV. The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis. Mult Scler 2013; 19 (12) 1571-1579
  • 33 Hedström AK, Hillert J, Olsson T, Alfredsson L. Smoking and multiple sclerosis susceptibility. Eur J Epidemiol 2013; 28 (11) 867-874
  • 34 Zhang P, Wang R, Li Z. , et al. The risk of smoking on multiple sclerosis: a meta-analysis based on 20,626 cases from case-control and cohort studies. Peer J 2016; 4: e1797
  • 35 Dobson R, Giovannoni G, Ramagopalan S. The month of birth effect in multiple sclerosis: systematic review, meta-analysis and effect of latitude. J Neurol Neurosurg Psychiatry 2013; 84 (04) 427-432
  • 36 Glenn JD, Mowry EM. Emerging concepts on the gut microbiome and multiple sclerosis. J Interferon Cytokine Res 2016; 36 (06) 347-357
  • 37 Kotzamani D, Panou T, Mastorodemos V. , et al. Rising incidence of multiple sclerosis in females associated with urbanization. Neurology 2012; 78 (22) 1728-1735
  • 38 Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005; 4 (05) 281-288
  • 39 Fisniku LK, Brex PA, Altmann DR. , et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008; 131 (Pt 3): 808-817
  • 40 Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003; 126 (Pt 4): 770-782
  • 41 Tintoré M, Rovira A, Río J. , et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006; 67 (06) 968-972
  • 42 Swanton JK, Fernando KT, Dalton CM. , et al. Early MRI in optic neuritis: the risk for clinically definite multiple sclerosis. Mult Scler 2010; 16 (02) 156-165
  • 43 Barkhof F, Filippi M, Miller DH. , et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997; 120 (Pt 11): 2059-2069
  • 44 Swanton JK, Fernando K, Dalton CM. , et al. Is the frequency of abnormalities on magnetic resonance imaging in isolated optic neuritis related to the prevalence of multiple sclerosis? A global comparison. J Neurol Neurosurg Psychiatry 2006; 77 (09) 1070-1072
  • 45 Mowry EM, Deen S, Malikova I, Pelletier J, Bacchetti P, Waubant E. The onset location of multiple sclerosis predicts the location of subsequent relapses. J Neurol Neurosurg Psychiatry 2009; 80 (04) 400-403
  • 46 Villar LM, García-Barragán N, Sádaba MC. , et al. Accuracy of CSF and MRI criteria for dissemination in space in the diagnosis of multiple sclerosis. J Neurol Sci 2008; 266 (1-2): 34-37
  • 47 Fahrbach K, Huelin R, Martin AL. , et al. Relating relapse and T2 lesion changes to disability progression in multiple sclerosis: a systematic literature review and regression analysis. BMC Neurol 2013; 13: 180
  • 48 Scalfari A, Neuhaus A, Daumer M, Deluca GC, Muraro PA, Ebers GC. Early relapses, onset of progression, and late outcome in multiple sclerosis. JAMA Neurol 2013; 70 (02) 214-222
  • 49 Lublin FD, Reingold SC. ; National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996; 46 (04) 907-911
  • 50 Lublin FD, Reingold SC, Cohen JA. , et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014; 83 (03) 278-286
  • 51 Okuda DT, Mowry EM, Beheshtian A. , et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology 2009; 72 (09) 800-805
  • 52 Okuda DT, Siva A, Kantarci O. , et al; Radiologically Isolated Syndrome Consortium (RISC); Club Francophone de la Sclérose en Plaques (CFSEP). Radiologically isolated syndrome: 5-year risk for an initial clinical event. PLoS One 2014; 9 (03) e90509
  • 53 Link H, Huang YM. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J Neuroimmunol 2006; 180 (1-2): 17-28
  • 54 Polman CH, Reingold SC, Banwell B. , et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69 (02) 292-302
  • 55 Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999; 53 (05) 1107-1114
  • 56 Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66 (10) 1485-1489
  • 57 Wingerchuk DM, Banwell B, Bennett JL. , et al; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85 (02) 177-189
  • 58 Boiko A, Vorobeychik G, Paty D, Devonshire V, Sadovnick D. ; University of British Columbia MS Clinic Neurologists. Early onset multiple sclerosis: a longitudinal study. Neurology 2002; 59 (07) 1006-1010
  • 59 Banwell B, Krupp L, Kennedy J. , et al. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol 2007; 6 (09) 773-781
  • 60 Yeh EA, Chitnis T, Krupp L. , et al; US Network of Pediatric Multiple Sclerosis Centers of Excellence. Pediatric multiple sclerosis. Nat Rev Neurol 2009; 5 (11) 621-631
  • 61 Huppke B, Ellenberger D, Rosewich H, Friede T, Gärtner J, Huppke P. Clinical presentation of pediatric multiple sclerosis before puberty. Eur J Neurol 2014; 21 (03) 441-446
  • 62 Banwell B, Kennedy J, Sadovnick D. , et al. Incidence of acquired demyelination of the CNS in Canadian children. Neurology 2009; 72 (03) 232-239
  • 63 Peche SS, Alshekhlee A, Kelly J, Lenox J, Mar S. A long-term follow-up study using IPMSSG criteria in children with CNS demyelination. Pediatr Neurol 2013; 49 (05) 329-334
  • 64 Callen DJ, Shroff MM, Branson HM. , et al. MRI in the diagnosis of pediatric multiple sclerosis. Neurology 2009; 72 (11) 961-967
  • 65 Lee CG, Lee B, Lee J, Lee M. The natural course of clinically isolated syndrome in pediatric patients. Brain Dev 2015; 37 (04) 432-438
  • 66 Renoux C, Vukusic S, Mikaeloff Y. , et al; Adult Neurology Departments KIDMUS Study Group. Natural history of multiple sclerosis with childhood onset. N Engl J Med 2007; 356 (25) 2603-2613
  • 67 Chitnis T, Krupp L, Yeh A. , et al. Pediatric multiple sclerosis. Neurol Clin 2011; 29 (02) 481-505
  • 68 Krupp LB, Tardieu M, Amato MP. , et al; International Pediatric Multiple Sclerosis Study Group. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 2013; 19 (10) 1261-1267
  • 69 Rubin JP, Kuntz NL. Diagnostic criteria for pediatric multiple sclerosis. Curr Neurol Neurosci Rep 2013; 13 (06) 354
  • 70 Chitnis T, Tenembaum S, Banwell B. , et al; International Pediatric Multiple Sclerosis Study Group. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult Scler 2012; 18 (01) 116-127
  • 71 Ghezzi A, Goretti B, Portaccio E, Roscio M, Amato MP. Cognitive impairment in pediatric multiple sclerosis. Neurol Sci 2010; 31 (Suppl. 02) S215-S218
  • 72 Chitnis T, Ghezzi A, Bajer-Kornek B, Boyko A, Giovannoni G, Pohl D. Pediatric multiple sclerosis: escalation and emerging treatments. Neurology 2016; 87 (09) (Suppl. 02) S103-S109
  • 73 Chitnis T. PARADIGMS: a randomised double-blind study of fingolimod versus interferon beta-1a in paediatric multiple sclerosis. Mult Scler 2017; 23 (S3): 977-978
  • 74 Jancic J, Nikolic B, Ivancevic N. , et al. Multiple sclerosis in pediatrics: current concepts and treatment options. Neurol Ther 2016; 5 (02) 131-143
  • 75 Filippini G, Brusaferri F, Sibley WA. , et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000; (04) CD001331
  • 76 Burton JM, O'Connor PW, Hohol M, Beyene J. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev 2012; 12: CD006921
  • 77 Weinshenker BG, O'Brien PC, Petterson TM. , et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46 (06) 878-886
  • 78 Weiner HL, Dau PC, Khatri BO. , et al. Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology 1989; 39 (09) 1143-1149
  • 79 The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43 (04) 655-661
  • 80 Jacobs LD, Cookfair DL, Rudick RA. , et al; The Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39 (03) 285-294
  • 81 Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 352 (9139): 1498-1504
  • 82 Johnson KP, Brooks BR, Cohen JA. , et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45 (07) 1268-1276
  • 83 Goodin DS, Reder AT, Ebers GC. , et al. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial. Neurology 2012; 78 (17) 1315-1322
  • 84 Calabresi PA, Kieseier BC, Arnold DL. , et al; ADVANCE Study Investigators. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol 2014; 13 (07) 657-665
  • 85 Khan O, Rieckmann P, Boyko A. , et al. Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study. Mult Scler 2017; 23 (06) 818-829
  • 86 O'Connor P, Wolinsky JS, Confavreux C. , et al; TEMSO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011; 365 (14) 1293-1303
  • 87 Confavreux C, O'Connor P, Comi G. , et al; TOWER Trial Group. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13 (03) 247-256
  • 88 Viglietta V, Miller D, Bar-Or A. , et al. Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials. Ann Clin Transl Neurol 2015; 2 (02) 103-118
  • 89 Baharnoori M, Lyons J, Dastagir A, Koralnik I, Stankiewicz JM. Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm 2016; 3 (05) e274
  • 90 Kappos L, Radue EW, O'Connor P. , et al; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362 (05) 387-401
  • 91 Cohen JA, Barkhof F, Comi G. , et al; TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362 (05) 402-415
  • 92 Berger JR. Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord 2017; 12: 59-63
  • 93 Polman CH, O'Connor PW, Havrdova E. , et al; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354 (09) 899-910
  • 94 Fernández O, Oreja-Guevara C, Arroyo R, Izquierdo G, Pérez JL, Montalban X. Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study. J Neurol 2012; 259 (09) 1814-1823
  • 95 Butzkueven H, Kappos L, Pellegrini F. , et al; TYSABRI Observational Program (TOP) Investigators. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry 2014; 85 (11) 1190-1197
  • 96 Sørensen PS, Bertolotto A, Edan G. , et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 2012; 18 (02) 143-152
  • 97 Schwab N, Schneider-Hohendorf T, Pignolet B. , et al. Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values. Neurol Neuroimmunol Neuroinflamm 2016; 3 (01) e195
  • 98 Alroughani R, Akhtar S, Ahmed SF. , et al. JC virus seroprevalence and seroconversion in multiple sclerosis cohort: a Middle-Eastern study. J Neurol Sci 2016; 360: 61-65
  • 99 Koendgen H. Chang I, Sperling B, et al. New algorithm to estimate risk of natalizumab-associated progressive multifocal leukoencephalopathy (PML) in antiJCV antibody positive patients: analyses of clinical trial data to provide further temporal precision and inform clinical practice. Mult Scler 2016; 22 (S3): 659
  • 100 Villar LM, Costa-Frossard L, Masterman T. , et al. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. Ann Neurol 2015; 77 (03) 447-457
  • 101 Schwab N, Schneider-Hohendorf T, Pignolet B. , et al. PML risk stratification using anti-JCV antibody index and L-selectin. Mult Scler 2016; 22 (08) 1048-1060
  • 102 Cohen JA, Coles AJ, Arnold DL. , et al; CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012; 380 (9856): 1819-1828
  • 103 Coles AJ, Twyman CL, Arnold DL. , et al; CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012; 380 (9856): 1829-1839
  • 104 Coles AJ, Cohen JA, Arnold DL. , et al. On behalf of the CARE-MS I Investigators. Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I). Mult Scler 2016; 22 (S3): 75
  • 105 Fox EJ, Alroughani R, Brassat D. , et al. On behalf of the CARE-MS II Investigators. Efficacy of alemtuzumab is durable over 6 years in patients with active relapsing-remitting multiple sclerosis and an inadequate response to prior therapy in the absence of continuous treatment (CARE-MS II). Mult Scler 2016; 22 (S3): 596
  • 106 Hauser SL, Bar-Or A, Comi G. , et al; OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 2017; 376 (03) 221-234
  • 107 Jacobs LD, Beck RW, Simon JH. , et al; CHAMPS Study Group. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000; 343 (13) 898-904
  • 108 Kappos L, Polman CH, Freedman MS. , et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67 (07) 1242-1249
  • 109 Comi G, Martinelli V, Rodegher M. , et al; PreCISe study group. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374 (9700): 1503-1511
  • 110 Comi G, De Stefano N, Freedman MS. , et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol 2012; 11 (01) 33-41
  • 111 Noyes K, Weinstock-Guttman B. Impact of diagnosis and early treatment on the course of multiple sclerosis. Am J Manag Care 2013; 19 (17, Suppl): s321-s331
  • 112 Sormani MP, Rio J, Tintorè M. , et al. Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler 2013; 19 (05) 605-612
  • 113 Freedman MS, Selchen D, Arnold DL. , et al; Canadian Multiple Sclerosis Working Group. Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci 2013; 40 (03) 307-323
  • 114 Freedman MS, Forrestal FG. Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon beta-1a: analysis of the PRISMS study. Mult Scler 2008; 14 (09) 1234-1241
  • 115 Yamout B, Alroughani R, Al-Jumah M. , et al. Consensus recommendations for the diagnosis and treatment of multiple sclerosis: the Middle East North Africa Committee for Treatment and Research In Multiple Sclerosis (MENACTRIMS). Curr Med Res Opin 2015; 31 (07) 1349-1361
  • 116 Montalban X, Hauser SL, Kappos L. , et al; ORATORIO Clinical Investigators. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017; 376 (03) 209-220
  • 117 Hawker K, O'Connor P, Freedman MS. , et al; OLYMPUS trial group. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66 (04) 460-471
  • 118 Tourbah A, Lebrun-Frenay C, Edan G. , et al; MS-SPI study group. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: a randomised, double-blind, placebo-controlled study. Mult Scler 2016; 22 (13) 1719-1731
  • 119 Kappos L, Bar-Or A, Cree BAC. , et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): A double blind, randomised, phase 3 study. Lancet 2018; 391: 1263-1273
  • 120 Hartung HP, Gonsette R, König N. , et al; Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360 (9350): 2018-2025
  • 121 Martinelli Boneschi F, Vacchi L, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev 2013; (05) CD002127
  • 122 Goodkin DE, Rudick RA, VanderBrug Medendorp S. , et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995; 37 (01) 30-40
  • 123 Zephir H, de Seze J, Duhamel A. , et al. Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients. J Neurol Sci 2004; 218 (1-2): 73-77
  • 124 Frohman EM, Brannon K, Racke MK, Hawker K. Mycophenolate mofetil in multiple sclerosis. Clin Neuropharmacol 2004; 27 (02) 80-83
  • 125 Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. ; Pregnancy in Multiple Sclerosis Group. Rate of pregnancy-related relapse in multiple sclerosis. N Engl J Med 1998; 339 (05) 285-291
  • 126 Hughes SE, Spelman T, Gray OM. , et al; MSBase study group. Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Mult Scler 2014; 20 (06) 739-746
  • 127 Finkelsztejn A, Brooks JB, Paschoal Jr FM, Fragoso YD. What can we really tell women with multiple sclerosis regarding pregnancy? A systematic review and meta-analysis of the literature. BJOG 2011; 118 (07) 790-797
  • 128 Houtchens MK, Kolb CM. Multiple sclerosis and pregnancy: therapeutic considerations. J Neurol 2013; 260 (05) 1202-1214
  • 129 Lu E, Wang BW, Guimond C, Synnes A, Sadovnick D, Tremlett H. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology 2012; 79 (11) 1130-1135
  • 130 Neudorfer O, Sandberg-Wollheim M, Coyle PK. , et al. The Glatiramer acetate pregnancy database. Mult Scler 2015; 21 (S11): 793
  • 131 Karlsson G, Francis G, Koren G. , et al. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology 2014; 82 (08) 674-680
  • 132 Pozzilli C, Pugliatti M. ; ParadigMS Group. An overview of pregnancy-related issues in patients with multiple sclerosis. Eur J Neurol 2015; 22 (Suppl. 02) 34-39
  • 133 Kieseier BC, Benamor M. Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing-remitting multiple sclerosis. Neurol Ther 2014; 3 (02) 133-138
  • 134 Gold R, Phillips JT, Havrdova E. , et al. Delayed-release dimethyl fumarate and pregnancy: preclinical studies and pregnancy outcomes from clinical trials and postmarketing experience. Neurol Ther 2015; 4 (02) 93-104
  • 135 Friend S, Richman S, Bloomgren G, Cristiano LM, Wenten M. Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study. BMC Neurol 2016; 16 (01) 150
  • 136 Haghikia A, Langer-Gould A, Rellensmann G. , et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurol 2014; 71 (07) 891-895
  • 137 Achiron A, Chambers C, Fox EJ. , et al. Pregnancy outcomes in patients with active RRMS who received alemtuzumab in the clinical development program. Mult Scler 2015; 21 (S11): 581
  • 138 Hviid A, Mølgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ 2011; 183 (07) 796-804
  • 139 Ray JG, Vermeulen MJ, Bharatha A, Montanera WJ, Park AL. Association between MRI exposure during pregnancy and fetal and childhood outcomes. JAMA 2016; 316 (09) 952-961
  • 140 Langer-Gould A, Huang SM, Gupta R. , et al. Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch Neurol 2009; 66 (08) 958-963
  • 141 Portaccio E, Ghezzi A, Hakiki B. , et al; MS Study Group of the Italian Neurological Society. Breastfeeding is not related to postpartum relapses in multiple sclerosis. Neurology 2011; 77 (02) 145-150
  • 142 Haas J, Hommes OR. A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis. Mult Scler 2007; 13 (07) 900-908
  • 143 Hellwig K, Beste C, Schimrigk S, Chan A. Immunomodulation and postpartum relapses in patients with multiple sclerosis. Ther Adv Neurol Disorder 2009; 2 (01) 7-11
  • 144 de Seze J, Chapelotte M, Delalande S, Ferriby D, Stojkovic T, Vermersch P. Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis. Mult Scler 2004; 10 (05) 596-597